ClearNote Health
San Diego, California, United States · Biotechnology, Health Care, Health Diagnostics · 55 employees
ClearNote Health is a privately held company dedicated to improving early detection and monitoring for some of the deadliest forms of cancer. Developed by scientists in the Stephen Quake laboratory at Stanford University, the company’s patented core Virtuoso® epigenomics platform utilizes advances in artificial intelligence and bioinformatics. Their noninvasive Avantect® tests are designed to iden
Funding history
- Series series d — $52.0M — May 2026
- Funding Round — $21.8M — Jun 2025
Recent signals
- May 27, 2026: Raised $52.0M in Series series d
- Mar 18, 2026: ClearNote Health Appoints Jeffrey Venstrom, MD, as Chief Medical Officer
- Jun 05, 2025: Raised $21.8M
- Mar 12, 2025: ClearNote Health's Avantect® Pancreatic Cancer Test Now Available to Health Plan Members Accessing Claritev's National PPO Networks
- Jan 07, 2025: Launched ClearNote Health Announces Avantect® Multi-Cancer Detection Test for National Cancer Institute's Vanguard Study.
See plans & pricing → Track ClearNote Health’s funding, hiring, and signals — with verified contacts — on Fundz.